Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

N/AEnrolling By InvitationNCT06925685

Allogene Therapeutics50 enrolled

Overview

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hematologic Malignancies Solid Tumors

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study Exclusion Criteria: * Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor

Locations (1)

Circuit Clinical

Buffalo, New York, United States

Outcomes

Primary Outcomes

Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs

Time frame: Up to 15 years post treatment with allogeneic CAR T-cell product

Overall survival (OS)

Time frame: Up to 15 years post treatment with allogeneic CAR T cell product

Presence of replication competent lentivirus (RCL) in blood

Time frame: Up to 15 years post treatment with allogeneic CAR T cell product

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.